Group 1 - China Rejuvenation Medicine (08158) announced the acquisition of 55% equity in Kangmeizhan Biotechnology Development Co., Ltd. for HKD 5.5 billion from China Star Entertainment (BVI) Limited [1] - Following the acquisition, China Rejuvenation and China Star will hold 55% and 45% stakes in Kangmeizhan, respectively [1] - A shareholders' agreement was established to regulate the rights and obligations of China Rejuvenation, China Star, and Kangmeizhan upon completion of the transaction [1] Group 2 - The strategic cooperation aims to leverage the strengths and resources of each party, enhancing competitiveness in the Macau market [2] - Kangmeizhan will benefit from the industry resources and experience of the group in aesthetic medical and beauty services, achieving synergistic effects [2] - This collaboration marks a significant milestone for the group in expanding into the new market of Macau, creating new market opportunities and business value for each company [2]
中国再生医学(08158)拟与China Star战略合作，收购康美赞55%股权